The Role of High Density Surface ECG in the Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

The Leeds Teaching Hospitals NHS Trust

Status: Completed

Conditions: Arrhythmogenic Right Ventricular Cardiomyopathy

Treatments: Device: 80 lead ECG

Study type: Interventional

Funder types: Other

Identifiers

NCT02291393

12/YH/0346 (Other Identifier)

CD12/10936

Details and patient eligibility

About

The diagnosis of Arrhythmogenic right ventricular cardiomyopathy can be difficult. The 80 lead ECG may increase the specificity and sensitivity in diagnosing this potentially life threatening inherited cardiac condition. This pilot would form the basis of a much larger clinical trial to test the utility of this novel diagnostic tool.

Enrollment: 20 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients with a confirmed diagnosis of arrhythmogenic right ventricular cardiomyopathy who are being followed up in the cardiology clinic

Exclusion criteria

• Inability to consent
• Pacing dependent patients
• Other concomitant cardiag disease e.g. coronary artery disease
• Atrial fibrillation

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 2 patient groups

Patient

Other group

Description:

Patients with previously confirmed Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

Treatment:

Device: 80 lead ECG

Healthy volunteers

Other group

Description:

Aged and gender matched healthy controls.

Treatment:

Device: 80 lead ECG